3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
19
Thyroid Neoplasms
7
Glioma
6
Thyroid Carcinoma, Anaplastic
5
Multiple Myeloma
5
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Thyroid Cancer, Papillary
3
Hematologic Neoplasms
3
Skin Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Glioblastoma
2
Colonic Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma, Follicular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Interventions
Fluorouracil
9
Oxaliplatin
7
Leucovorin
7
Surveys and Questionnaires
6
Blood Specimen Collection
6
Bevacizumab
6
Specimen Handling
5
Gemcitabine
5
Cetuximab
5
Capecitabine
5
fludarabine
4
aldesleukin
4
Standard of Care
4
Irinotecan
4
Cyclophosphamide
4
Remote Patient Monitoring
3
Radiosurgery
3
Pafolacianine
3
Nivolumab
3
Endoscopic Mucosal Resection
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
encorafenib
2
Tomography, X-Ray Computed
2
Sunitinib
2
Referral and Consultation
2
Radiotherapy
2
Practice Guidelines as Topic
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
dabrafenib
×
1 year
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled